nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—Methoxsalen—psoriasis	0.165	0.264	CbGbCtD
Arformoterol—CYP2A6—Prednisolone—psoriasis	0.0802	0.128	CbGbCtD
Arformoterol—CYP2D6—Hydroxyurea—psoriasis	0.0567	0.0907	CbGbCtD
Arformoterol—CYP2A6—Dexamethasone—psoriasis	0.0473	0.0756	CbGbCtD
Arformoterol—CYP2C19—Cholecalciferol—psoriasis	0.0452	0.0723	CbGbCtD
Arformoterol—CYP2C9—Cholecalciferol—psoriasis	0.0376	0.0601	CbGbCtD
Arformoterol—CYP2D6—Cholecalciferol—psoriasis	0.0344	0.055	CbGbCtD
Arformoterol—CYP2C19—Prednisone—psoriasis	0.0313	0.0501	CbGbCtD
Arformoterol—CYP2C19—Cyclosporine—psoriasis	0.0297	0.0475	CbGbCtD
Arformoterol—CYP2C9—Cyclosporine—psoriasis	0.0247	0.0395	CbGbCtD
Arformoterol—CYP2D6—Cyclosporine—psoriasis	0.0226	0.0361	CbGbCtD
Arformoterol—CYP2C19—Dexamethasone—psoriasis	0.0196	0.0313	CbGbCtD
Arformoterol—CYP2C9—Dexamethasone—psoriasis	0.0163	0.026	CbGbCtD
Arformoterol—CYP2D6—Dexamethasone—psoriasis	0.0149	0.0238	CbGbCtD
Arformoterol—CYP2A6—CYP2E1 reactions—CYP2S1—psoriasis	0.00266	0.102	CbGpPWpGaD
Arformoterol—CYP2A6—Xenobiotics—CYP2S1—psoriasis	0.00165	0.063	CbGpPWpGaD
Arformoterol—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00162	0.0619	CbGpPWpGaD
Arformoterol—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00149	0.057	CbGpPWpGaD
Arformoterol—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00148	0.0565	CbGpPWpGaD
Arformoterol—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.00139	0.0531	CbGpPWpGaD
Arformoterol—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.00101	0.0384	CbGpPWpGaD
Arformoterol—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000925	0.0353	CbGpPWpGaD
Arformoterol—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000917	0.035	CbGpPWpGaD
Arformoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000685	0.0261	CbGpPWpGaD
Arformoterol—CYP2A6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000676	0.0258	CbGpPWpGaD
Arformoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000555	0.0212	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000429	0.0164	CbGpPWpGaD
Arformoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000418	0.0159	CbGpPWpGaD
Arformoterol—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000412	0.0157	CbGpPWpGaD
Arformoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000384	0.0147	CbGpPWpGaD
Arformoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000381	0.0145	CbGpPWpGaD
Arformoterol—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000379	0.0145	CbGpPWpGaD
Arformoterol—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000376	0.0143	CbGpPWpGaD
Arformoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000339	0.0129	CbGpPWpGaD
Arformoterol—ADRB1—Melatonin metabolism and effects—APOE—psoriasis	0.000327	0.0125	CbGpPWpGaD
Arformoterol—ADRB1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000317	0.0121	CbGpPWpGaD
Arformoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000311	0.0119	CbGpPWpGaD
Arformoterol—ADRB2—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	0.000311	0.0118	CbGpPWpGaD
Arformoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000309	0.0118	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—CYP2S1—psoriasis	0.000295	0.0113	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000284	0.0109	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000274	0.0104	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000248	0.00948	CbGpPWpGaD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000231	0.00883	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.000226	0.00863	CbGpPWpGaD
Arformoterol—ADRB1—Melatonin metabolism and effects—NFKB1—psoriasis	0.000195	0.00743	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.00018	0.00686	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000177	0.00677	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—HCAR2—psoriasis	0.000176	0.00672	CbGpPWpGaD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000175	0.00668	CbGpPWpGaD
Arformoterol—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000174	0.00665	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—HCAR2—psoriasis	0.000172	0.00657	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.000165	0.00631	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—TGFA—psoriasis	0.000164	0.00627	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000164	0.00626	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000163	0.00623	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000162	0.00617	CbGpPWpGaD
Arformoterol—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.00016	0.00612	CbGpPWpGaD
Arformoterol—Constipation—Cyclosporine—psoriasis	0.000135	0.000389	CcSEcCtD
Arformoterol—Pain—Cyclosporine—psoriasis	0.000135	0.000389	CcSEcCtD
Arformoterol—Dry mouth—Triamcinolone—psoriasis	0.000135	0.000388	CcSEcCtD
Arformoterol—Angioedema—Betamethasone—psoriasis	0.000135	0.000387	CcSEcCtD
Arformoterol—Angioedema—Dexamethasone—psoriasis	0.000135	0.000387	CcSEcCtD
Arformoterol—Diarrhoea—Mycophenolic acid—psoriasis	0.000134	0.000385	CcSEcCtD
Arformoterol—Conjunctivitis—Methotrexate—psoriasis	0.000133	0.000383	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000133	0.000383	CcSEcCtD
Arformoterol—Immune system disorder—Prednisone—psoriasis	0.000133	0.000382	CcSEcCtD
Arformoterol—Malaise—Dexamethasone—psoriasis	0.000133	0.000382	CcSEcCtD
Arformoterol—Malaise—Betamethasone—psoriasis	0.000133	0.000382	CcSEcCtD
Arformoterol—Anaphylactic shock—Triamcinolone—psoriasis	0.000133	0.000381	CcSEcCtD
Arformoterol—Oedema—Triamcinolone—psoriasis	0.000133	0.000381	CcSEcCtD
Arformoterol—Pain—Mycophenolate mofetil—psoriasis	0.000132	0.00038	CcSEcCtD
Arformoterol—Constipation—Mycophenolate mofetil—psoriasis	0.000132	0.00038	CcSEcCtD
Arformoterol—Arrhythmia—Prednisone—psoriasis	0.000132	0.000378	CcSEcCtD
Arformoterol—Infection—Triamcinolone—psoriasis	0.000132	0.000378	CcSEcCtD
Arformoterol—Hypotension—Hydrocortisone—psoriasis	0.000132	0.000378	CcSEcCtD
Arformoterol—Haematuria—Methotrexate—psoriasis	0.000131	0.000376	CcSEcCtD
Arformoterol—Feeling abnormal—Cyclosporine—psoriasis	0.000131	0.000375	CcSEcCtD
Arformoterol—Insomnia—Prednisolone—psoriasis	0.00013	0.000374	CcSEcCtD
Arformoterol—Gastrointestinal pain—Cyclosporine—psoriasis	0.00013	0.000372	CcSEcCtD
Arformoterol—Dizziness—Mycophenolic acid—psoriasis	0.00013	0.000372	CcSEcCtD
Arformoterol—Tachycardia—Triamcinolone—psoriasis	0.000129	0.000372	CcSEcCtD
Arformoterol—Mental disorder—Prednisone—psoriasis	0.000129	0.000371	CcSEcCtD
Arformoterol—Malnutrition—Prednisone—psoriasis	0.000128	0.000369	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000128	0.000368	CcSEcCtD
Arformoterol—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000127	0.000366	CcSEcCtD
Arformoterol—Insomnia—Hydrocortisone—psoriasis	0.000127	0.000366	CcSEcCtD
Arformoterol—Hypertension—Dexamethasone—psoriasis	0.000127	0.000365	CcSEcCtD
Arformoterol—Hypertension—Betamethasone—psoriasis	0.000127	0.000365	CcSEcCtD
Arformoterol—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.000126	0.000363	CcSEcCtD
Arformoterol—Urticaria—Cyclosporine—psoriasis	0.000126	0.000361	CcSEcCtD
Arformoterol—Myalgia—Betamethasone—psoriasis	0.000125	0.00036	CcSEcCtD
Arformoterol—Myalgia—Dexamethasone—psoriasis	0.000125	0.00036	CcSEcCtD
Arformoterol—Abdominal pain—Cyclosporine—psoriasis	0.000125	0.00036	CcSEcCtD
Arformoterol—Body temperature increased—Cyclosporine—psoriasis	0.000125	0.00036	CcSEcCtD
Arformoterol—Anxiety—Dexamethasone—psoriasis	0.000125	0.000359	CcSEcCtD
Arformoterol—Anxiety—Betamethasone—psoriasis	0.000125	0.000359	CcSEcCtD
Arformoterol—Vomiting—Mycophenolic acid—psoriasis	0.000125	0.000358	CcSEcCtD
Arformoterol—Discomfort—Dexamethasone—psoriasis	0.000124	0.000356	CcSEcCtD
Arformoterol—Discomfort—Betamethasone—psoriasis	0.000124	0.000356	CcSEcCtD
Arformoterol—Dyspepsia—Hydrocortisone—psoriasis	0.000124	0.000356	CcSEcCtD
Arformoterol—Rash—Mycophenolic acid—psoriasis	0.000123	0.000355	CcSEcCtD
Arformoterol—Dermatitis—Mycophenolic acid—psoriasis	0.000123	0.000354	CcSEcCtD
Arformoterol—Pain—Prednisolone—psoriasis	0.000123	0.000354	CcSEcCtD
Arformoterol—Urticaria—Mycophenolate mofetil—psoriasis	0.000123	0.000353	CcSEcCtD
Arformoterol—Headache—Mycophenolic acid—psoriasis	0.000123	0.000352	CcSEcCtD
Arformoterol—Pharyngitis—Methotrexate—psoriasis	0.000122	0.000351	CcSEcCtD
Arformoterol—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000122	0.000351	CcSEcCtD
Arformoterol—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000122	0.000351	CcSEcCtD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000122	0.00465	CbGpPWpGaD
Arformoterol—Urinary tract disorder—Methotrexate—psoriasis	0.000122	0.000349	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000122	0.000349	CcSEcCtD
Arformoterol—Fatigue—Hydrocortisone—psoriasis	0.000121	0.000349	CcSEcCtD
Arformoterol—Urethral disorder—Methotrexate—psoriasis	0.000121	0.000347	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000121	0.000347	CcSEcCtD
Arformoterol—Pain—Hydrocortisone—psoriasis	0.00012	0.000346	CcSEcCtD
Arformoterol—Anaphylactic shock—Betamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Arformoterol—Anaphylactic shock—Dexamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Arformoterol—Oedema—Dexamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Arformoterol—Oedema—Betamethasone—psoriasis	0.00012	0.000345	CcSEcCtD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00012	0.00458	CbGpPWpGaD
Arformoterol—Insomnia—Triamcinolone—psoriasis	0.00012	0.000344	CcSEcCtD
Arformoterol—Infection—Betamethasone—psoriasis	0.00012	0.000343	CcSEcCtD
Arformoterol—Infection—Dexamethasone—psoriasis	0.00012	0.000343	CcSEcCtD
Arformoterol—Ill-defined disorder—Prednisone—psoriasis	0.000119	0.000342	CcSEcCtD
Arformoterol—Feeling abnormal—Prednisolone—psoriasis	0.000119	0.000341	CcSEcCtD
Arformoterol—Visual impairment—Methotrexate—psoriasis	0.000119	0.000341	CcSEcCtD
Arformoterol—Dyspnoea—Triamcinolone—psoriasis	0.000118	0.000339	CcSEcCtD
Arformoterol—Nervous system disorder—Betamethasone—psoriasis	0.000118	0.000339	CcSEcCtD
Arformoterol—Nervous system disorder—Dexamethasone—psoriasis	0.000118	0.000339	CcSEcCtD
Arformoterol—Agitation—Prednisone—psoriasis	0.000118	0.000339	CcSEcCtD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.000118	0.00448	CbGpPWpGaD
Arformoterol—Tachycardia—Dexamethasone—psoriasis	0.000117	0.000337	CcSEcCtD
Arformoterol—Tachycardia—Betamethasone—psoriasis	0.000117	0.000337	CcSEcCtD
Arformoterol—Angioedema—Prednisone—psoriasis	0.000117	0.000337	CcSEcCtD
Arformoterol—Hypersensitivity—Cyclosporine—psoriasis	0.000117	0.000335	CcSEcCtD
Arformoterol—Dyspepsia—Triamcinolone—psoriasis	0.000117	0.000335	CcSEcCtD
Arformoterol—Nausea—Mycophenolic acid—psoriasis	0.000116	0.000334	CcSEcCtD
Arformoterol—Feeling abnormal—Hydrocortisone—psoriasis	0.000116	0.000333	CcSEcCtD
Arformoterol—Malaise—Prednisone—psoriasis	0.000116	0.000332	CcSEcCtD
Arformoterol—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000115	0.000331	CcSEcCtD
Arformoterol—Urticaria—Prednisolone—psoriasis	0.000115	0.000329	CcSEcCtD
Arformoterol—Cardiac disorder—Methotrexate—psoriasis	0.000114	0.000328	CcSEcCtD
Arformoterol—Fatigue—Triamcinolone—psoriasis	0.000114	0.000328	CcSEcCtD
Arformoterol—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.000114	0.000327	CcSEcCtD
Arformoterol—Asthenia—Cyclosporine—psoriasis	0.000114	0.000326	CcSEcCtD
Arformoterol—Pain—Triamcinolone—psoriasis	0.000113	0.000326	CcSEcCtD
Arformoterol—Hypotension—Betamethasone—psoriasis	0.000112	0.000323	CcSEcCtD
Arformoterol—Hypotension—Dexamethasone—psoriasis	0.000112	0.000323	CcSEcCtD
Arformoterol—Pruritus—Cyclosporine—psoriasis	0.000112	0.000322	CcSEcCtD
Arformoterol—Urticaria—Hydrocortisone—psoriasis	0.000112	0.000321	CcSEcCtD
Arformoterol—Immune system disorder—Methotrexate—psoriasis	0.000111	0.00032	CcSEcCtD
Arformoterol—Abdominal pain—Hydrocortisone—psoriasis	0.000111	0.00032	CcSEcCtD
Arformoterol—Body temperature increased—Hydrocortisone—psoriasis	0.000111	0.00032	CcSEcCtD
Arformoterol—Mediastinal disorder—Methotrexate—psoriasis	0.000111	0.000319	CcSEcCtD
Arformoterol—Asthenia—Mycophenolate mofetil—psoriasis	0.000111	0.000318	CcSEcCtD
Arformoterol—Hypertension—Prednisone—psoriasis	0.000111	0.000318	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.00011	0.000315	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Betamethasone—psoriasis	0.00011	0.000315	CcSEcCtD
Arformoterol—Pruritus—Mycophenolate mofetil—psoriasis	0.000109	0.000314	CcSEcCtD
Arformoterol—Myalgia—Prednisone—psoriasis	0.000109	0.000314	CcSEcCtD
Arformoterol—Arthralgia—Prednisone—psoriasis	0.000109	0.000314	CcSEcCtD
Arformoterol—Feeling abnormal—Triamcinolone—psoriasis	0.000109	0.000314	CcSEcCtD
Arformoterol—Anxiety—Prednisone—psoriasis	0.000109	0.000313	CcSEcCtD
Arformoterol—Insomnia—Dexamethasone—psoriasis	0.000109	0.000312	CcSEcCtD
Arformoterol—Insomnia—Betamethasone—psoriasis	0.000109	0.000312	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000109	0.000312	CcSEcCtD
Arformoterol—Diarrhoea—Cyclosporine—psoriasis	0.000108	0.000311	CcSEcCtD
Arformoterol—Discomfort—Prednisone—psoriasis	0.000108	0.00031	CcSEcCtD
Arformoterol—Mental disorder—Methotrexate—psoriasis	0.000108	0.00031	CcSEcCtD
Arformoterol—Malnutrition—Methotrexate—psoriasis	0.000107	0.000308	CcSEcCtD
Arformoterol—Hypersensitivity—Prednisolone—psoriasis	0.000106	0.000305	CcSEcCtD
Arformoterol—Dyspepsia—Betamethasone—psoriasis	0.000106	0.000304	CcSEcCtD
Arformoterol—Dyspepsia—Dexamethasone—psoriasis	0.000106	0.000304	CcSEcCtD
Arformoterol—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000106	0.000304	CcSEcCtD
Arformoterol—Urticaria—Triamcinolone—psoriasis	0.000105	0.000302	CcSEcCtD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—TP53—psoriasis	0.000105	0.00401	CbGpPWpGaD
Arformoterol—Dysgeusia—Methotrexate—psoriasis	0.000105	0.000302	CcSEcCtD
Arformoterol—Body temperature increased—Triamcinolone—psoriasis	0.000105	0.000301	CcSEcCtD
Arformoterol—Dizziness—Cyclosporine—psoriasis	0.000105	0.000301	CcSEcCtD
Arformoterol—Oedema—Prednisone—psoriasis	0.000105	0.000301	CcSEcCtD
Arformoterol—Anaphylactic shock—Prednisone—psoriasis	0.000105	0.000301	CcSEcCtD
Arformoterol—Infection—Prednisone—psoriasis	0.000104	0.000299	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Betamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Arformoterol—Back pain—Methotrexate—psoriasis	0.000104	0.000298	CcSEcCtD
Arformoterol—Hypersensitivity—Hydrocortisone—psoriasis	0.000104	0.000298	CcSEcCtD
Arformoterol—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	0.000104	0.00396	CbGpPWpGaD
Arformoterol—Fatigue—Dexamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Arformoterol—Fatigue—Betamethasone—psoriasis	0.000104	0.000298	CcSEcCtD
Arformoterol—Pain—Dexamethasone—psoriasis	0.000103	0.000295	CcSEcCtD
Arformoterol—Pain—Betamethasone—psoriasis	0.000103	0.000295	CcSEcCtD
Arformoterol—Nervous system disorder—Prednisone—psoriasis	0.000103	0.000295	CcSEcCtD
Arformoterol—Tachycardia—Prednisone—psoriasis	0.000102	0.000294	CcSEcCtD
Arformoterol—Dizziness—Mycophenolate mofetil—psoriasis	0.000102	0.000293	CcSEcCtD
Arformoterol—Skin disorder—Prednisone—psoriasis	0.000102	0.000292	CcSEcCtD
Arformoterol—Asthenia—Hydrocortisone—psoriasis	0.000101	0.00029	CcSEcCtD
Arformoterol—Vomiting—Cyclosporine—psoriasis	0.000101	0.000289	CcSEcCtD
Arformoterol—Rash—Cyclosporine—psoriasis	9.99e-05	0.000287	CcSEcCtD
Arformoterol—Dermatitis—Cyclosporine—psoriasis	9.98e-05	0.000287	CcSEcCtD
Arformoterol—Pruritus—Hydrocortisone—psoriasis	9.96e-05	0.000286	CcSEcCtD
Arformoterol—ADRB1—GPCR downstream signaling—HCAR2—psoriasis	9.96e-05	0.0038	CbGpPWpGaD
Arformoterol—Ill-defined disorder—Methotrexate—psoriasis	9.95e-05	0.000286	CcSEcCtD
Arformoterol—Headache—Cyclosporine—psoriasis	9.93e-05	0.000285	CcSEcCtD
Arformoterol—Feeling abnormal—Dexamethasone—psoriasis	9.91e-05	0.000285	CcSEcCtD
Arformoterol—Feeling abnormal—Betamethasone—psoriasis	9.91e-05	0.000285	CcSEcCtD
Arformoterol—Gastrointestinal pain—Betamethasone—psoriasis	9.84e-05	0.000282	CcSEcCtD
Arformoterol—Gastrointestinal pain—Dexamethasone—psoriasis	9.84e-05	0.000282	CcSEcCtD
Arformoterol—Vomiting—Mycophenolate mofetil—psoriasis	9.83e-05	0.000282	CcSEcCtD
Arformoterol—Hypersensitivity—Triamcinolone—psoriasis	9.77e-05	0.00028	CcSEcCtD
Arformoterol—Rash—Mycophenolate mofetil—psoriasis	9.75e-05	0.00028	CcSEcCtD
Arformoterol—ADRB2—GPCR downstream signaling—HCAR2—psoriasis	9.74e-05	0.00372	CbGpPWpGaD
Arformoterol—Dermatitis—Mycophenolate mofetil—psoriasis	9.74e-05	0.00028	CcSEcCtD
Arformoterol—Headache—Mycophenolate mofetil—psoriasis	9.68e-05	0.000278	CcSEcCtD
Arformoterol—Malaise—Methotrexate—psoriasis	9.67e-05	0.000278	CcSEcCtD
Arformoterol—Diarrhoea—Hydrocortisone—psoriasis	9.63e-05	0.000277	CcSEcCtD
Arformoterol—Urticaria—Betamethasone—psoriasis	9.56e-05	0.000274	CcSEcCtD
Arformoterol—Urticaria—Dexamethasone—psoriasis	9.56e-05	0.000274	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Prednisone—psoriasis	9.55e-05	0.000274	CcSEcCtD
Arformoterol—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	9.54e-05	0.00364	CbGpPWpGaD
Arformoterol—Dizziness—Prednisolone—psoriasis	9.53e-05	0.000274	CcSEcCtD
Arformoterol—Asthenia—Triamcinolone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Arformoterol—Body temperature increased—Dexamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Arformoterol—Abdominal pain—Dexamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Arformoterol—Body temperature increased—Betamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Arformoterol—Abdominal pain—Betamethasone—psoriasis	9.51e-05	0.000273	CcSEcCtD
Arformoterol—Insomnia—Prednisone—psoriasis	9.48e-05	0.000272	CcSEcCtD
Arformoterol—Nausea—Cyclosporine—psoriasis	9.41e-05	0.00027	CcSEcCtD
Arformoterol—Pruritus—Triamcinolone—psoriasis	9.38e-05	0.000269	CcSEcCtD
Arformoterol—Cough—Methotrexate—psoriasis	9.36e-05	0.000269	CcSEcCtD
Arformoterol—Dizziness—Hydrocortisone—psoriasis	9.31e-05	0.000267	CcSEcCtD
Arformoterol—Dyspepsia—Prednisone—psoriasis	9.22e-05	0.000265	CcSEcCtD
Arformoterol—Nausea—Mycophenolate mofetil—psoriasis	9.18e-05	0.000264	CcSEcCtD
Arformoterol—ADRB1—GPCR ligand binding—CCL20—psoriasis	9.15e-05	0.00349	CbGpPWpGaD
Arformoterol—Chest pain—Methotrexate—psoriasis	9.13e-05	0.000262	CcSEcCtD
Arformoterol—Arthralgia—Methotrexate—psoriasis	9.13e-05	0.000262	CcSEcCtD
Arformoterol—Myalgia—Methotrexate—psoriasis	9.13e-05	0.000262	CcSEcCtD
Arformoterol—Rash—Prednisolone—psoriasis	9.09e-05	0.000261	CcSEcCtD
Arformoterol—Dermatitis—Prednisolone—psoriasis	9.08e-05	0.000261	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	9.07e-05	0.00026	CcSEcCtD
Arformoterol—ADRB1—Signaling by GPCR—HCAR2—psoriasis	9.04e-05	0.00345	CbGpPWpGaD
Arformoterol—Fatigue—Prednisone—psoriasis	9.03e-05	0.000259	CcSEcCtD
Arformoterol—Headache—Prednisolone—psoriasis	9.03e-05	0.000259	CcSEcCtD
Arformoterol—Discomfort—Methotrexate—psoriasis	9.02e-05	0.000259	CcSEcCtD
Arformoterol—Constipation—Prednisone—psoriasis	8.96e-05	0.000257	CcSEcCtD
Arformoterol—Vomiting—Hydrocortisone—psoriasis	8.95e-05	0.000257	CcSEcCtD
Arformoterol—ADRB2—GPCR ligand binding—CCL20—psoriasis	8.95e-05	0.00341	CbGpPWpGaD
Arformoterol—Rash—Hydrocortisone—psoriasis	8.88e-05	0.000255	CcSEcCtD
Arformoterol—Dermatitis—Hydrocortisone—psoriasis	8.87e-05	0.000255	CcSEcCtD
Arformoterol—ADRB2—Signaling by GPCR—HCAR2—psoriasis	8.84e-05	0.00337	CbGpPWpGaD
Arformoterol—Headache—Hydrocortisone—psoriasis	8.82e-05	0.000253	CcSEcCtD
Arformoterol—Dizziness—Triamcinolone—psoriasis	8.77e-05	0.000252	CcSEcCtD
Arformoterol—Anaphylactic shock—Methotrexate—psoriasis	8.76e-05	0.000251	CcSEcCtD
Arformoterol—Infection—Methotrexate—psoriasis	8.7e-05	0.00025	CcSEcCtD
Arformoterol—Feeling abnormal—Prednisone—psoriasis	8.63e-05	0.000248	CcSEcCtD
Arformoterol—Asthenia—Dexamethasone—psoriasis	8.63e-05	0.000248	CcSEcCtD
Arformoterol—Asthenia—Betamethasone—psoriasis	8.63e-05	0.000248	CcSEcCtD
Arformoterol—Nervous system disorder—Methotrexate—psoriasis	8.59e-05	0.000247	CcSEcCtD
Arformoterol—Gastrointestinal pain—Prednisone—psoriasis	8.57e-05	0.000246	CcSEcCtD
Arformoterol—Nausea—Prednisolone—psoriasis	8.56e-05	0.000246	CcSEcCtD
Arformoterol—Pruritus—Dexamethasone—psoriasis	8.51e-05	0.000244	CcSEcCtD
Arformoterol—Pruritus—Betamethasone—psoriasis	8.51e-05	0.000244	CcSEcCtD
Arformoterol—Skin disorder—Methotrexate—psoriasis	8.5e-05	0.000244	CcSEcCtD
Arformoterol—Vomiting—Triamcinolone—psoriasis	8.43e-05	0.000242	CcSEcCtD
Arformoterol—Nausea—Hydrocortisone—psoriasis	8.36e-05	0.00024	CcSEcCtD
Arformoterol—Rash—Triamcinolone—psoriasis	8.36e-05	0.00024	CcSEcCtD
Arformoterol—Dermatitis—Triamcinolone—psoriasis	8.35e-05	0.00024	CcSEcCtD
Arformoterol—Urticaria—Prednisone—psoriasis	8.32e-05	0.000239	CcSEcCtD
Arformoterol—Headache—Triamcinolone—psoriasis	8.31e-05	0.000239	CcSEcCtD
Arformoterol—Abdominal pain—Prednisone—psoriasis	8.28e-05	0.000238	CcSEcCtD
Arformoterol—Body temperature increased—Prednisone—psoriasis	8.28e-05	0.000238	CcSEcCtD
Arformoterol—Diarrhoea—Betamethasone—psoriasis	8.23e-05	0.000236	CcSEcCtD
Arformoterol—Diarrhoea—Dexamethasone—psoriasis	8.23e-05	0.000236	CcSEcCtD
Arformoterol—Hypotension—Methotrexate—psoriasis	8.18e-05	0.000235	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Methotrexate—psoriasis	7.98e-05	0.000229	CcSEcCtD
Arformoterol—Dizziness—Betamethasone—psoriasis	7.96e-05	0.000228	CcSEcCtD
Arformoterol—Dizziness—Dexamethasone—psoriasis	7.96e-05	0.000228	CcSEcCtD
Arformoterol—Insomnia—Methotrexate—psoriasis	7.92e-05	0.000227	CcSEcCtD
Arformoterol—Nausea—Triamcinolone—psoriasis	7.88e-05	0.000226	CcSEcCtD
Arformoterol—Dyspnoea—Methotrexate—psoriasis	7.81e-05	0.000224	CcSEcCtD
Arformoterol—Somnolence—Methotrexate—psoriasis	7.78e-05	0.000224	CcSEcCtD
Arformoterol—Hypersensitivity—Prednisone—psoriasis	7.72e-05	0.000222	CcSEcCtD
Arformoterol—Dyspepsia—Methotrexate—psoriasis	7.71e-05	0.000221	CcSEcCtD
Arformoterol—Vomiting—Dexamethasone—psoriasis	7.65e-05	0.00022	CcSEcCtD
Arformoterol—Vomiting—Betamethasone—psoriasis	7.65e-05	0.00022	CcSEcCtD
Arformoterol—Rash—Dexamethasone—psoriasis	7.59e-05	0.000218	CcSEcCtD
Arformoterol—Rash—Betamethasone—psoriasis	7.59e-05	0.000218	CcSEcCtD
Arformoterol—Dermatitis—Betamethasone—psoriasis	7.58e-05	0.000218	CcSEcCtD
Arformoterol—Dermatitis—Dexamethasone—psoriasis	7.58e-05	0.000218	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Methotrexate—psoriasis	7.56e-05	0.000217	CcSEcCtD
Arformoterol—Fatigue—Methotrexate—psoriasis	7.55e-05	0.000217	CcSEcCtD
Arformoterol—Headache—Dexamethasone—psoriasis	7.54e-05	0.000216	CcSEcCtD
Arformoterol—Headache—Betamethasone—psoriasis	7.54e-05	0.000216	CcSEcCtD
Arformoterol—Asthenia—Prednisone—psoriasis	7.52e-05	0.000216	CcSEcCtD
Arformoterol—Pain—Methotrexate—psoriasis	7.49e-05	0.000215	CcSEcCtD
Arformoterol—Pruritus—Prednisone—psoriasis	7.41e-05	0.000213	CcSEcCtD
Arformoterol—Feeling abnormal—Methotrexate—psoriasis	7.22e-05	0.000207	CcSEcCtD
Arformoterol—Diarrhoea—Prednisone—psoriasis	7.17e-05	0.000206	CcSEcCtD
Arformoterol—Gastrointestinal pain—Methotrexate—psoriasis	7.16e-05	0.000206	CcSEcCtD
Arformoterol—Nausea—Betamethasone—psoriasis	7.15e-05	0.000205	CcSEcCtD
Arformoterol—Nausea—Dexamethasone—psoriasis	7.15e-05	0.000205	CcSEcCtD
Arformoterol—Urticaria—Methotrexate—psoriasis	6.96e-05	0.0002	CcSEcCtD
Arformoterol—Dizziness—Prednisone—psoriasis	6.93e-05	0.000199	CcSEcCtD
Arformoterol—Abdominal pain—Methotrexate—psoriasis	6.92e-05	0.000199	CcSEcCtD
Arformoterol—Body temperature increased—Methotrexate—psoriasis	6.92e-05	0.000199	CcSEcCtD
Arformoterol—Vomiting—Prednisone—psoriasis	6.66e-05	0.000191	CcSEcCtD
Arformoterol—Rash—Prednisone—psoriasis	6.61e-05	0.00019	CcSEcCtD
Arformoterol—Dermatitis—Prednisone—psoriasis	6.6e-05	0.00019	CcSEcCtD
Arformoterol—Headache—Prednisone—psoriasis	6.56e-05	0.000188	CcSEcCtD
Arformoterol—Hypersensitivity—Methotrexate—psoriasis	6.45e-05	0.000185	CcSEcCtD
Arformoterol—Asthenia—Methotrexate—psoriasis	6.28e-05	0.00018	CcSEcCtD
Arformoterol—Nausea—Prednisone—psoriasis	6.22e-05	0.000179	CcSEcCtD
Arformoterol—Pruritus—Methotrexate—psoriasis	6.19e-05	0.000178	CcSEcCtD
Arformoterol—Diarrhoea—Methotrexate—psoriasis	5.99e-05	0.000172	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—NDUFA5—psoriasis	5.93e-05	0.00226	CbGpPWpGaD
Arformoterol—Dizziness—Methotrexate—psoriasis	5.79e-05	0.000166	CcSEcCtD
Arformoterol—Vomiting—Methotrexate—psoriasis	5.57e-05	0.00016	CcSEcCtD
Arformoterol—Rash—Methotrexate—psoriasis	5.52e-05	0.000159	CcSEcCtD
Arformoterol—Dermatitis—Methotrexate—psoriasis	5.52e-05	0.000158	CcSEcCtD
Arformoterol—Headache—Methotrexate—psoriasis	5.49e-05	0.000158	CcSEcCtD
Arformoterol—ADRB1—Signaling Pathways—HCAR2—psoriasis	5.34e-05	0.00204	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HCAR2—psoriasis	5.22e-05	0.00199	CbGpPWpGaD
Arformoterol—Nausea—Methotrexate—psoriasis	5.2e-05	0.000149	CcSEcCtD
Arformoterol—ADRB1—GPCR downstream signaling—CCL20—psoriasis	5.17e-05	0.00197	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CCL20—psoriasis	5.06e-05	0.00193	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP2S1—psoriasis	5.05e-05	0.00193	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CCL20—psoriasis	4.7e-05	0.00179	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TAGAP—psoriasis	4.63e-05	0.00177	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CCL20—psoriasis	4.59e-05	0.00175	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TAGAP—psoriasis	4.53e-05	0.00173	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NDUFA5—psoriasis	3.62e-05	0.00138	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.37e-05	0.00129	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NDUFA5—psoriasis	3.33e-05	0.00127	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NDUFA5—psoriasis	3.3e-05	0.00126	CbGpPWpGaD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.24e-05	0.00124	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.17e-05	0.00121	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP2S1—psoriasis	3.08e-05	0.00117	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.08e-05	0.00117	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2S1—psoriasis	2.83e-05	0.00108	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2S1—psoriasis	2.81e-05	0.00107	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCL20—psoriasis	2.77e-05	0.00106	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCL20—psoriasis	2.71e-05	0.00104	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—CXCL8—psoriasis	2.47e-05	0.000943	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CARM1—psoriasis	2.46e-05	0.00094	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—CXCL8—psoriasis	2.42e-05	0.000922	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.61e-05	0.000615	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SOCS1—psoriasis	1.53e-05	0.000583	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CAT—psoriasis	1.52e-05	0.000578	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CARM1—psoriasis	1.5e-05	0.000573	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SOCS1—psoriasis	1.49e-05	0.00057	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.47e-05	0.000561	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—TYK2—psoriasis	1.46e-05	0.000556	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—TYK2—psoriasis	1.42e-05	0.000544	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.4e-05	0.000536	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—CXCL8—psoriasis	1.4e-05	0.000533	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CARM1—psoriasis	1.38e-05	0.000527	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CARM1—psoriasis	1.37e-05	0.000523	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CXCL8—psoriasis	1.37e-05	0.000521	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.28e-05	0.000489	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCL8—psoriasis	1.27e-05	0.000484	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCL8—psoriasis	1.24e-05	0.000473	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—APOE—psoriasis	1.18e-05	0.000449	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—LEP—psoriasis	1.13e-05	0.00043	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APOE—psoriasis	1.13e-05	0.00043	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—LEP—psoriasis	1.1e-05	0.000421	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APOE—psoriasis	1.1e-05	0.000421	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NFKBIA—psoriasis	1.05e-05	0.000401	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NFKBIA—psoriasis	1.03e-05	0.000392	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARG—psoriasis	1.03e-05	0.000391	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CAT—psoriasis	9.24e-06	0.000353	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TYK2—psoriasis	8.6e-06	0.000328	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CAT—psoriasis	8.5e-06	0.000324	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CAT—psoriasis	8.43e-06	0.000321	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TYK2—psoriasis	8.42e-06	0.000321	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—psoriasis	7.49e-06	0.000286	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—psoriasis	7.33e-06	0.00028	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—APOE—psoriasis	7.18e-06	0.000274	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—psoriasis	7.12e-06	0.000272	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—psoriasis	6.97e-06	0.000266	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—psoriasis	6.96e-06	0.000266	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—psoriasis	6.81e-06	0.00026	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NFKB1—psoriasis	6.7e-06	0.000256	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—APOE—psoriasis	6.6e-06	0.000252	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NFKB1—psoriasis	6.56e-06	0.00025	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—APOE—psoriasis	6.55e-06	0.00025	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARG—psoriasis	6.25e-06	0.000239	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—psoriasis	6.08e-06	0.000232	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—psoriasis	6.02e-06	0.00023	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—psoriasis	5.95e-06	0.000227	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—psoriasis	5.89e-06	0.000225	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARG—psoriasis	5.75e-06	0.000219	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARG—psoriasis	5.7e-06	0.000218	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—psoriasis	4.6e-06	0.000175	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—psoriasis	4.5e-06	0.000172	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—psoriasis	4.21e-06	0.000161	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—psoriasis	4.12e-06	0.000157	CbGpPWpGaD
